SGLT2i与RAASi及其联合用药对糖尿病肾脏病高钾血症风险的影响:网络Meta分析
该网络Meta分析纳入27项研究、43589例糖尿病肾脏病患者,比较SGLT2i与RAASi各种联合方案对高钾血症发生的影响。结果显示,在ACEI或ARB基础上加用MRA显著增加高钾血症风险,而SGLT2i与ACEI、ARB、双RAASi或MRA/肾素抑制剂联合ACEI/ARB相比高钾血症发生率显著更低,且加用SGLT2i可显著降低MRA联合ACEI/ARB等方案的高钾血症发生。
要点
- ACEI或ARB基础上加用MRA较安慰剂显著增加高钾血症风险(OR 6.08,95%CI 2.30至16.08)。
- SGLT2i较ACEI、ARB、双RAASi及MRA或肾素抑制剂联合ACEI/ARB的高钾血症发生率显著更低。
- 在MRA联合ACEI/ARB及不同RAASi联合方案中加用SGLT2i可显著降低高钾血症发生。
核心结论
- 在糖尿病肾脏病患者中,MRA在ACEI或ARB基础上增加高钾血症风险,而SGLT2i作用相反,并可逆转包括MRA在内的联合方案所致的血钾升高。
研究设计与样本
- 网络Meta分析,纳入27项合格研究、共43589例糖尿病肾脏病患者;采用随机效应模型比较高钾血症风险,结果以OR及95%CI表示,并用累积排序概率曲线下面积对各类药物及其与安慰剂联合方案的效果排序。
主要发现
- 在ACEI或ARB基础上加用MRA较安慰剂(OR 6.08,95%CI 2.30至16.08)、ACEI(OR 3.07,95%CI 1.14至8.31)、ARB(OR 2.57,95%CI 1.10至6.02)、SGLT2i(OR 9.22,95%CI 2.99至28.46)、肾素抑制剂+ACEI/ARB(OR 2.23,95%CI 1.14至4.36)或SGLT2i+ACEI/ARB(OR 4.10,95%CI 2.32至7.26)显著增加高钾血症发生率。
- 不同代MRA的亚组分析显示,螺内酯与ACEI/ARB联合时效应最强,甚至高于ACEI与ARB联合使用(OR 2.89,95%CI 1.26至6.63)。
- SGLT2i较ACEI(OR 0.33,95%CI 0.12至0.91)、ARB(OR 0.28,95%CI 0.13至0.61)、双RAASi即ACEI联合ARB(OR 0.17,95%CI 0.06至0.47)、MRA联合ACEI/ARB(OR 0.11,95%CI 0.04至0.33)或肾素抑制剂联合ACEI/ARB(OR 0.24,95%CI 0.08至0.76)的高钾血症发生率显著更低。
- 在MRA联合ACEI/ARB方案以及不同RAASi联合方案中加用SGLT2i可显著降低高钾血症的发生。
关键数值与推荐
- 在ACEI或ARB基础上加用MRA较安慰剂的高钾血症OR为6.08(95%CI 2.30至16.08)。
- 螺内酯联合ACEI/ARB较ACEI联合ARB的高钾血症OR为2.89(95%CI 1.26至6.63)。
- SGLT2i较双RAASi(ACEI联合ARB)的高钾血症OR为0.17(95%CI 0.06至0.47)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This network meta-analysis investigated the effect of various combined regimens of sodium-glucose cotransporter-2 inhibitors (SGLT2is) and renin-angiotensin-aldosterone system inhibitors (RAASis) on the occurrence of hyperkalemia in diabetic kidney disease. METHODS: The risk of hyperkalemia was compared using the random-effects model of network meta-analysis, with results expressed as odds ratios (ORs) with 95% confidence intervals (CIs). The comparative effects of all medications and their combinations with placebo were ranked using the surface under the cumulative ranking probabilities. RESULTS: In total, 27 eligible studies involving 43,589 participants with diabetic kidney disease were included. Major findings showed that the use of mineralocorticoid receptor antagonists (MRAs) on top of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) prominently increased hyperkalemia incidence when compared with placebo (OR, 6.08; 95% CI, 2.30 to 16.08), ACEI (OR, 3.07; 95% CI, 1.14 to 8.31), ARB (OR, 2.57; 95% CI, 1.10 to 6.02), SGLT2i (OR, 9.22; 95% CI, 2.99 to 28.46), renin inhibitors+ACEI/ARB (OR, 2.23; 95% CI, 1.14 to 4.36), or SGLT2i+ACEI/ARB (OR, 4.10; 95% CI, 2.32 to 7.26). Subgroup analysis among different generations of MRA found that spironolactone had the strongest effect in combination with ACEI/ARB, even higher than the combined use of ACEI and ARB (OR, 2.89; 95% CI, 1.26 to 6.63). In addition, SGLT2i had a significantly lower incidence of hyperkalemia compared with ACEI (OR, 0.33; 95% CI, 0.12 to 0.91), ARB (OR, 0.28; 95% CI, 0.13 to 0.61), dual RAASi (ACEI combined with ARB; OR, 0.17; 95% CI, 0.06 to 0.47), or MRA or renin inhibitors combined with ACEI/ARB (OR, 0.11; 95% CI, 0.04 to 0.33; OR, 0.24; 95% CI, 0.08 to 0.76, respectively). Moreover, adding SGLT2i to the combination of MRA and ACEI/ARB, as well as the combinations of different RAASis, markedly reduced the occurrence of hyperkalemia. CONCLUSIONS: Among the therapeutic drugs with the potential risk of increasing serum potassium in patients with diabetic kidney disease, MRA added an extra risk of hyperkalemia while SGLT2i had the opposite effect and could even reverse the elevation of serum potassium caused by the combined regimen, including MRAs.
引用
- Luo X, Xu J, Zhou S, et al. Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD: A Network Meta-Analysis. Clin J Am Soc Nephrol. 2023. PMID: 37256921. doi:10.2215/CJN.0000000000000205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。